metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			DCR
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	camrelizumab alone vs. Standard of Care (SoC)	1	-
	nivolumab alone vs. Standard of Care (SoC)	1
	pembrolizumab alone vs. Standard of Care (SoC)	1	-